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Man with Syncope
Emily Lai MD, PGY-2 and Anita Mehrotra MD, PGY-1

Mr. K, a 57 year-old Caucasian male with a history of
coronary artery disease, dilated ischemic cardiomyopathy, ventricular fibrillation arrest status post
implantable cardioverter defibrillator (ICD) placement
was admitted to telemetry for two syncopal episodes. The
patient described multiple episodes of dizziness with
fatigue over the week prior to admission, the last two
episodes resulting in loss of consciousness with bladder
incontinence. He was home alone when these episodes
occurred and was unsure of how long he had been
unconscious. Mr. K was not aware of any recent firing of
his ICD. He denied any shortness of breath, chest pain,
diaphoresis, recent fevers or chills.
His medical history was significant for hypertension,
coronary artery disease status post two vessel coronary
artery bypass grafting, dilated cardiomyopathy, and
ventricular fibrillation arrest with subsequent ICD
placement four years ago. His most recent echocardiogram was four years ago, showing an ejection fraction
of 15%. The patient’s medications included enalapril,
carvedilol, amiodarone, warfarin, ezetimibe, digoxin,

atorvastatin, furosemide, aspirin and niacin. He had no
known drug allergies. Mr. K was a retired train
conductor. He smoked half of a pack of cigarettes a day
and had an 80 pack-year smoking history. He had a
history of alcohol, cocaine, and amphetamine abuse, but
he quit these drugs 15 years prior. He denied any history
of intravenous drug use.
Physical examination on admission was significant for
elevated jugular venous pressure, a grade II/VI systolic
ejection murmur over the left sternal border, diffuse
wheezes on lung exam, and 2+ lower extremity edema.
Laboratory results showed a B-type natriuretic peptide
level of 662 pg/ml, a creatinine of 1.0 mg/dL, and a
digoxin level of 1.6 ng/mL. Chest X-ray showed
moderate pulmonary edema. His electrocardiogram
(ECG) is shown in Figure 1.
The patient was admitted to telemetry and ruled out for
myocardial infarction by serial enzymes. His ICD was
interrogated on hospital day 1, revealing three episodes
of ventricular tachycardia, which correlated with his

Figure 1
(Continued on next page)

20

Pulse: EKG

(Continued from previous page)

symptoms. The settings of his ICD were adjusted, and
the electrophysiology service recommended reloading
the patient with oral amiodarone. The patient was
started on amiodarone 400 mg three times a day for the
next five days. For treatment of his congestive heart
failure exacerbation, the patient was diuresed with
intravenous furosemide with a goal negative balance of
one to two liters per day. The patient was also started
on nebulizers for suspected chronic obstructive
pulmonary disease and spironolactone to optimize his
heart failure regimen. The patient reported feeling
improvement over the next four days.
On the morning of hospital day #5, Mr. K complained
of feeling very uncomfortable with a sensation of fullness
and bloating in his abdomen, which the patient
attributed to being constipated. He reported no bowel
movements in the past few days. He also complained of
increased weakness, shortness of breath and an episode
of chills, nausea and emesis overnight. On physical exam,
he was afebrile, heart rate was 60 beats per minute and
blood pressure was 124/77 mmHg. His abdomen was
distended but nontender with active bowel sounds. No
rebound or guarding was present. An arterial blood gas
was attempted but was felt to be venous. The pH of the
venous blood gas was 7.37. Stool softeners and laxatives
were ordered and an extra dose of furosemide was given.
A few hours later, the patient called the nurse complaining
of feeling poorly. The nurse noted the patient to be
diaphoretic and cyanotic. She attempted to take his blood
pressure and could not detect a pressure by manual cuff.
The primary team was called to evaluate the patient and
detected a systolic blood pressure of 54 mmHg by doppler.
A fluid bolus of one liter of normal saline was given with
improvement of the systolic blood pressure to 82 mmHg
by doppler. The patient complained of an uncontrollable
gasping for air but denied any chest pain. Central venous
access was obtained, and the critical care unit team was
called to evaluate the patient for hypotension and cyanosis.
Physical examination revealed the patient to be alert in
moderate distress with cyanotic lips. After a one liter fluid
bolus, the patient had a heart rate of 70 beats per minute
and respirations were 30 breaths per minute. A pulse
oximetry reading was unobtainable due to cyanotic
extremities. Jugular venous pressure was estimated at
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10mmHg. The systolic murmur was unchanged from prior
exams. Lung exam demonstrated wheezes diffusely with
1+ lower extremity edema. A stat echocardiogram was
ordered to evaluate the possibility of cardiac tamponade
given the patient’s hypotension. Echocardiogram showed
an ejection fraction of 10%, severe left ventricular
enlargement with global dysfunction, mild to moderate
mitral regurgitation, but no pericardial effusion.
An electrocardiogram was obtained and is shown in
Figure 2. Compared to his previous ECG on admission
which showed mostly ventricular paced beats, the patient
now had a sinus rhythm with widened QRS complexes
(duration 640ms) and peaked T waves. Hyperkalemia
was suspected, and the patient was given two ampules of
calcium gluconate and 10 units of insulin intravenously
with one ampule of dextrose 50%. The patient’s blood
pressure fell to the 70s/40s mmHg and continous
dopamine infusion was started. The patient was placed
on a 100% non-rebreather mask and urgently transferred
to the cardiac intensive care unit.
Stat laboratory results returned showing the serum
potassium to be 6.8 meq/L (compared to 4.0 meq/L the
day before), serum bicarbonate of 19 meq/L (previously
31 meq/L), calcium 2.0 mg/dL (from 4.2 mg/dL) and
creatinine of 1.7 mg/dL (from 1.0 mg/dL). The patient
was given three more ampules of calcium gluconate and
two ampules of sodium bicarbonate for his hyperkalemia.
Approximately 10 minutes after arrival to the CCU, the
patient began to complain of extreme shortness of breath.
His heart rate rapidly decreased to the 50s, and the
patient became unresponsive and pulseless.
Cardiopulmonary resuscitation was initiated for pulseless
electrical activity and three doses of epinephrine were
given. The patient’s rhythm converted to pulseless
ventricular fibrillation, and defibrillation was attempted
three times without change in rhythm or recovery of
pulse. An intravenous bolus of amiodarone was also given
without any response. Resuscitative efforts were
continued for 20 minutes before the patient was
pronounced dead.
Discussion
Post-mortem, a serum digoxin level sent earlier that
morning showed a level of 5.8 ng/ml. This level was well
above the upper limit of therapeutic (0.5 to 2 ng/ml).

Pulse: EKG

Figure 2

Digoxin toxicity was likely a contributing factor in this
unfortunate case. The patient had multiple known risk
factors for digoxin toxicity, including cardiac disease,
potential electrolyte abnormalities from diuresis, acute
renal insufficiency, and the addition of medications that
interfere with digoxin metabolism.
Digoxin acts by inhibiting the sodium-potassium
adenosine triphosphatase (ATP-ase) pump in myocytes.
With each action potential, sodium enters but a
decreased amount of sodium exits leading to an increase
in intracellular sodium and a decrease in intracellular
potassium. Through the sodium-calcium exchange, the
increase in sodium results in increased intracellular
calcium. This increases myocardial contractility and
enhances automaticity while slowing conduction
through the atrioventricular node. The decrease in
intracellular potassium may cause a relative increase in
extracellular potassium leading to elevated serum
potassium levels.
The most important method of diagnosing digoxin
toxicity is to maintain a high level of suspicion. Signs
and symptoms of digoxin toxicity are often subtle and
nonspecific. Patients may experience nausea, vomiting,

abdominal pain, fatigue, blurred vision, headache,
dizziness, confusion, delirium, and altered color vision
(classically described as seeing yellow halos around
lights). No single ECG abnormality is pathognomonic
of digoxin excess. However, the combination of
enhanced automaticity and impaired conduction (e.g.,
atrioventricular (AV) block accompanied by an
accelerated junctional pacemaker) is highly suggestive of
toxicity even when serum levels are within the “accepted”
therapeutic range. The first presenting sign of digoxin
toxicity may be a cardiac arrhythmia. Almost any
arrhythmia may be associated with digoxin toxicity,
though the most frequent is ventricular ectopy. Sinus
bradycardia, sinus arrest, paroxysmal atrial tachycardia,
heart block, junctional rhythms, ventricular tachycardia
and fibrillation are also commonly seen.
Digoxin is excreted through the kidneys proportional to
the glomerular filtration rate and is therefore dependent
on creatinine clearance. Renal insufficiency is then a
predisposing factor for digoxin toxicity. In our patient,
the acute renal insufficiency was likely secondary to
aggressive diuresis.
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Table 1. Commonly Used Medications that Affect Digoxin Level
Drug

Effect

Mechanism

Amiodarone
Verapamil
Diltiazem
Spironolactone
Indomethacin
Cyclosporine
Tetracycline
Cholestyramine
Rifampin

Increases
Increases
Increases
Increases
Increases
Increases
Increases
Decreases
Decreases

↓ renal clearance
↓ renal clearance
↓ renal clearance
↓ renal clearance
↓ renal clearance
↓ renal clearance
Altered gut flora
↓ gut absorption
Induction of
gut P-glycoprotein

Amiodarone, among many other drugs, is known to
increase serum digoxin levels though decreased renal
excretion at the tubular level and may also displace
bound digoxin from tissue. (See Table 1 for a list of other
commonly used medications that affect digoxin levels.)
It is recommended that patients being started on
amiodarone should have their maintenance doses of
digoxin decreased by 50 percent with close monitoring
of serum digoxin levels. In our patient, his maintenance
digoxin dose while on amiodarone 200 mg daily was
0.25 mg with a digoxin level within therapeutic range
(1.6 ng/mL). He was also started on spironolactone
during his hospitalization, which like amiodarone,
increases digoxin levels by decreasing renal clearance. The
patient’s rapid increase in serum digoxin level was likely
due to decreased renal excretion from the combination
of the oral amiodarone load, the addition of spironolactone, and acute renal failure.
As previously mentioned, digoxin toxicity may also be
associated with hyperkalemia by inhibiting sodiumpotassium exchange into the myocyte. In this case, Mr.
K had three potential causes of hyperkalemia: acute renal
failure, spironolactone use, and digoxin toxicity. The
treatment he received for his hyperkalemia included
multiple ampules of calcium gluconate which may have
further potentiated the effects of digoxin.
Elevated serum calcium levels increase ventricular
automaticity and this effect is at least additive to, and may
be synergistic with, the effects of digoxin. Administration
of intravenous calcium to patients taking digoxin may
provoke lethal ventricular arrhythmias, in particular,
refractory ventricular tachycardia and fibrillation. Thus,
calcium gluconate administration is problematic in
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hyperkalemia if digoxin toxicity is suspected and generally
not recommended. In Mr. K’s case, the cause of his cardiac
arrest may have been primarily hyperkalemia which would
correlate with his rhythm of pulseless electrical activity.
However, his rhythm then converted to ventricular
fibrillation that was unchanged after multiple attempts at
defibrillation. This may have been the effect of the five
ampules of calcium gluconate that were unknowingly
administered in the context of digoxin toxicity.
In severe cases of digoxin toxicity, digoxin-specific
antibody fragments (Digibind) may be used to treat
patients. Digibind rapidly binds circulating digoxin (as
digoxin has an increased affinity for the antibody fragment
over the sodium-potassium pumps) thus inactivating the
drug. Indications for use of Digibind include an acute
ingestion of greater than 10 mg of digoxin, plasma digoxin
levels greater than 10ng/ml, and potassium levels greater
than 5meq/L in the presence of a life-threatening
arrhythmia, as in this case. The antibody fragments are
given intravenously over 30 minutes, unless cardiac arrest
has occurred, in which case the solution is given as a bolus.
Side effects are few with Digibind but include worsening
congestive heart failure and hypokalemia.
Would the outcome of Mr. K’s case have been different
if digoxin toxicity had been suspected and Digibind
administered? We hope that by highlighting this case of
digoxin toxicity with associated hyperkalemia, we will
heighten awareness for the diagnosis and never have to
ask ourselves this question in the future.
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